 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michel Mikhail, Ph.D. as Chief Regulatory Officer of Navidea, effective October 1, 2021. Dr. Mikhail has more than 30 years of experience in the pharmaceutical industry and a track record of achievement in RD and international regulatory affairs 